afatinib + bevacizumab

Afatinib + bevacizumab is a combination therapy consisting of afatinib, an irreversible small molecule tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) family, and bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. This combination has been investigated primarily for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), especially in patients who have developed resistance to prior EGFR-TKI therapies such as osimertinib. Clinical studies suggest that this regimen may provide clinical benefit by overcoming acquired resistance mechanisms and prolonging progression-free survival in selected patient populations. The most common adverse events are diarrhea, skin rash/acne, paronychia, stomatitis, and hypertension; most are manageable with appropriate supportive care[1][3][5][6].